Rituximab treatment in adults with refractory minimal change disease or focal segmental glomerulosclerosis
Rituximab treatment in adults with refractory minimal change disease or focal segmental glomerulosclerosis is a paper indexed in ScholarIQ from OpenAlex.
How many citations does Rituximab treatment in adults with refractory minimal change disease or focal segmental glomerulosclerosis have?
Rituximab treatment in adults with refractory minimal change disease or focal segmental glomerulosclerosis has 27 citations in the OpenAlex counts ScholarIQ stores.
When was Rituximab treatment in adults with refractory minimal change disease or focal segmental glomerulosclerosis published?
Rituximab treatment in adults with refractory minimal change disease or focal segmental glomerulosclerosis has 2017 year in the ScholarIQ index.
What is the open-access status of Rituximab treatment in adults with refractory minimal change disease or focal segmental glomerulosclerosis?
Rituximab treatment in adults with refractory minimal change disease or focal segmental glomerulosclerosis has diamond oa status in the ScholarIQ index.
What is the DOI of Rituximab treatment in adults with refractory minimal change disease or focal segmental glomerulosclerosis?
The DOI for Rituximab treatment in adults with refractory minimal change disease or focal segmental glomerulosclerosis is on the source record.
What is the PMID of Rituximab treatment in adults with refractory minimal change disease or focal segmental glomerulosclerosis?
The PMID for Rituximab treatment in adults with refractory minimal change disease or focal segmental glomerulosclerosis is on the source record.
What is the OpenAlex record for Rituximab treatment in adults with refractory minimal change disease or focal segmental glomerulosclerosis?
The OpenAlex for Rituximab treatment in adults with refractory minimal change disease or focal segmental glomerulosclerosis is on the source record.